Post-approval trials of new medicines: widening use or deepening knowledge? Analysis of 10 years of etanercept (Q44566796)

4 December 2017

title

Post-approval trials of new medicines: widening use or deepening knowledge? Analysis of 10 years of etanercept (English)

1 reference

randomized controlled trial

4 December 2017

main subject

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20858147

17 July 2024

author name string

J. C F. van Luijn

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20858147

17 July 2024

M. Danz

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20858147

17 July 2024

J. W J. Bijlsma

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20858147

17 July 2024

F. W J. Gribnau

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20858147

17 July 2024

H. G M. Leufkens

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20858147

17 July 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20858147

17 July 2024

publication date

21 September 2010

1 reference

full work available at URL

4 December 2017

http://www.tandfonline.com/doi/pdf/10.3109/03009742.2010.509102

1 reference

https://api.crossref.org/works/10.3109/03009742.2010.509102

Scandinavian Journal of Rheumatology

17 July 2024

published in

1 reference

4 December 2017

volume

40

1 reference

4 December 2017

issue

3

1 reference

4 December 2017

page(s)

183-191

1 reference

Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

Diffusion of new technology and payment policies: coronary stents

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

Developing a center for comparative effectiveness information

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

Open label extension studies: research or marketing?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

Consent to open label extension studies: some ethical issues

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

A randomized trial of etanercept as monotherapy for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

Etanercept plus standard therapy for Wegener's granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

Effects of etanercept in patients with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

Evidence of a role of tumor necrosis factor alpha in refractory asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

Etanercept treatment for autoimmune inner ear disease: results of a pilot placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

A double-blind, placebo-controlled, dose-response pilot study evaluating intradiscal etanercept in patients with chronic discogenic low back pain or lumbosacral radiculopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

Efficacy of Etanercept in Preventing Relapse of Uveitis Controlled by Methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

Effect of tumor necrosis factor antagonism on allergen-mediated asthmatic airway inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

Use of volumetric computerized tomography as a primary outcome measure to evaluate drug efficacy in the prevention of peri-prosthetic osteolysis: a 1-year clinical pilot of etanercept vs. placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

Optimal use of methotrexate: the advantages of tight control

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

Direct versus indirect comparisons: a summary of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

Regulatory considerations for determining postmarketing study commitments

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

Presentation and analysis of data on radiographic outcome in clinical trials: experience from the TEMPO study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

Observational research, randomised trials, and two views of medical science

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.509102

Debate about funding comparative-effectiveness research

21 January 2018

4

1 reference

https://api.crossref.org/works/10.3109/03009742.2010.509102

Reform of drug regulation--beyond an independent drug-safety board

17 July 2024

5

1 reference

https://api.crossref.org/works/10.3109/03009742.2010.509102

Anticytokine therapy--a new era in the treatment of rheumatoid arthritis?

17 July 2024

8

1 reference

https://api.crossref.org/works/10.3109/03009742.2010.509102

Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group

17 July 2024

12

1 reference

https://api.crossref.org/works/10.3109/03009742.2010.509102

Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion Protein

17 July 2024

13

1 reference

https://api.crossref.org/works/10.3109/03009742.2010.509102

Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma

17 July 2024

17

1 reference

https://api.crossref.org/works/10.3109/03009742.2010.509102

Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group

17 July 2024

18

1 reference

https://api.crossref.org/works/10.3109/03009742.2010.509102

Recombinant human tumor necrosis factor receptor Fc fusion protein therapy in kidney transplant recipients undergoing OKT3 induction therapy

17 July 2024

19

1 reference

https://api.crossref.org/works/10.3109/03009742.2010.509102

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis

17 July 2024

20

1 reference

https://api.crossref.org/works/10.3109/03009742.2010.509102

Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes

17 July 2024

23

1 reference

https://api.crossref.org/works/10.3109/03009742.2010.509102

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

17 July 2024

25

1 reference

https://api.crossref.org/works/10.3109/03009742.2010.509102

Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression

17 July 2024

26

1 reference

https://api.crossref.org/works/10.3109/03009742.2010.509102

Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha

17 July 2024

29

1 reference

https://api.crossref.org/works/10.3109/03009742.2010.509102

Etanercept as monotherapy in patients with psoriasis

17 July 2024

31

1 reference

https://api.crossref.org/works/10.3109/03009742.2010.509102

Etanercept Treatment for Children and Adolescents with Plaque Psoriasis

17 July 2024

32

1 reference

https://api.crossref.org/works/10.3109/03009742.2010.509102

A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction

17 July 2024

33

1 reference

https://api.crossref.org/works/10.3109/03009742.2010.509102

Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial

17 July 2024

35

1 reference

https://api.crossref.org/works/10.3109/03009742.2010.509102

Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure

17 July 2024

41

1 reference

https://api.crossref.org/works/10.3109/03009742.2010.509102

Effect of blockade of TNF-alpha and interleukin-1 action on bone resorption in early postmenopausal women

17 July 2024

42

1 reference

https://api.crossref.org/works/10.3109/03009742.2010.509102

Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis

17 July 2024

48

1 reference

https://api.crossref.org/works/10.3109/03009742.2010.509102

The Journal of Rheumatology

17 July 2024

51

32

98

Melikoglu M

2005

1 reference

https://api.crossref.org/works/10.3109/03009742.2010.509102

Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients

17 July 2024

52

1 reference

https://api.crossref.org/works/10.3109/03009742.2010.509102

Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial

17 July 2024

57

1 reference

https://api.crossref.org/works/10.3109/03009742.2010.509102

Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis factor alpha, and markers of immune activation in HIV-infected subjects receiving interleukin 2

17 July 2024

59

1 reference

https://api.crossref.org/works/10.3109/03009742.2010.509102

A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis

17 July 2024

60

1 reference

https://api.crossref.org/works/10.3109/03009742.2010.509102

The effect of etanercept on cardiac transplant recipients: a study of TNFalpha antagonism and cardiac allograft hypertrophy

17 July 2024

61

1 reference

https://api.crossref.org/works/10.3109/03009742.2010.509102

A randomized, controlled study of a single intra-articular injection of etanercept or glucocorticosteroids in patients with rheumatoid arthritis

17 July 2024

63

1 reference

https://api.crossref.org/works/10.3109/03009742.2010.509102

Annals of the Rheumatic Diseases

17 July 2024

67

67

iii2

Furst DE

2008

1 reference

https://api.crossref.org/works/10.3109/03009742.2010.509102

Annals of the Rheumatic Diseases

17 July 2024

69

64

iv2

Furst DE

2005

1 reference

https://api.crossref.org/works/10.3109/03009742.2010.509102

Annals of the Rheumatic Diseases

17 July 2024

73

62

ii13

Hochberg MC

2003

1 reference

https://api.crossref.org/works/10.3109/03009742.2010.509102

Paying for drug approvals--who's using whom?

17 July 2024

79

1 reference

https://api.crossref.org/works/10.3109/03009742.2010.509102

Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial.

17 July 2024

84

1 reference

https://api.crossref.org/works/10.3109/03009742.2010.509102

The Journal of Rheumatology

17 July 2024

89

31

1356

Mease PJ

2004

1 reference

https://api.crossref.org/works/10.3109/03009742.2010.509102

17 July 2024

Identifiers

1 reference

4 December 2017

1 reference